Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    Only $9.99/month after trial. Cancel anytime.

    Fast Facts: Myelofibrosis: Reviewed by Professor Ruben A. Mesa
    Fast Facts: Myelofibrosis: Reviewed by Professor Ruben A. Mesa
    Fast Facts: Myelofibrosis: Reviewed by Professor Ruben A. Mesa
    Ebook142 pages1 hour

    Fast Facts: Myelofibrosis: Reviewed by Professor Ruben A. Mesa

    By Donal McLornan and Claire N. Harrison

    ()

    Read preview

    About this ebook

    GB
    LanguageEnglish
    PublisherS. Karger
    Release dateMay 31, 2022
    ISBN9783318071092
    Fast Facts: Myelofibrosis: Reviewed by Professor Ruben A. Mesa

    Related to Fast Facts

    Related ebooks

    Medical For You

    View More
    View More

    Related podcast episodes

    Related articles

    • Article

      SAINTS & COWBOYS

      Oct 5, 2023

      SAINTS & COWBOYS
      12 min read

    • Article

      What Defines a Stem Cell?

      Dec 27, 2018

      For the past three years, researchers at the Hubrecht Institute in the Netherlands have been painstakingly cataloging and mapping all the proliferating cells found in mouse hearts, looking for cardiac stem cells. The elusive cells should theoreticall

      5 min read

    • Article

      THE renaissance OF CELL THERAPIES

      Jul 28, 2019

      DR MARKUS DEPFENHART, PLASTIC AND AESTHETIC SURGEN In the late 1990s and early 2000s, there was huge hype around stem cells and their apparently almost unlimited potential, but unfortunately the expectations didn’t materialise. However, new scientifi

      2 min read

    • Article

      Coping with RECTAL CANCER

      Jun 8, 2022

      Coping with RECTAL CANCER
      2 min read

    • Article

      Beware Of Killer Genes

      Mar 18, 2019

      Beware Of Killer Genes
      2 min read

    • Article

      Groundbreaking Research

      Apr 19, 2019

      Groundbreaking Research
      2 min read

    • Article

      Healing The Whole Person

      Jul 24, 2022

      The UK National Health Service reports that one in two people in the UK will develop cancer at some time in their lives. This is a stark and rather frightening statistic, not only because cancer is a leading cause of death but also because the usual

      7 min read

    • Article

      Coping with... LUNG CANCER

      Jan 13, 2021

      Primary lung cancer is the third commonest cancer in the UK. Around 47,000 UK people are diagnosed yearly, with 45% aged 75 or over, and slightly more men than women. More than 70 out of 100 UK lung cancer cases are caused by smoking. Other risks inc

      1 min read

    • Article

      Thrombotic Thrombocytopenic Purpura (TTP) – a Rare Presentation with COVID-19

      Sep 1, 2022

      1 Department of General Medicine, Aster MIMS Hospital, Kozhikode, Kerala, India 2 Department of Nephrology, Aster MIMS Hospital, Kozhikode, Kerala, India Dr. Jabir M P, Consultant, Department of General Medicine, Aster MIMS, Kozhikode-673016 Email: j

      5 min read

    • Article

      Monochorionic Twin Pregnancy Complicated by Selective Intrauterine Growth Restriction with Co-existent Twin-to-twin Transfusion Syndrome

      Nov 6, 2020

      Corresponding author Dr Roopa R Shinde Specialist, Fetal medicine, Institute – Medcare Women and Children, Dubai Email: [email protected] Key words Monochorionic twin, twin to twin transfusion syndrome, selective intra uterine restrict

      5 min read

    • Article

      This Leukemia Comes With 600% Higher Risk Of Melanoma

      Aug 14, 2018

      People with chronic lymphocytic leukemia (CLL) have a 600 percent higher risk of melanoma, the most dangerous form of skin cancer, a new study reports. The higher melanoma risk isn’t news, but no one has reported a full analysis of detection rates an

      2 min read

    • Article

      COPING WITH... Leukaemia

      Aug 6, 2020

      COPING WITH... Leukaemia
      2 min read

    • Article

      DNA Test Beats Microscopes For Predicting Cancer’s Comeback

      Sep 25, 2018

      A DNA-based analysis of blood cells soon after a stem cell transplant can predict the likelihood of disease recurrence in people with a group of cancerous disorders related to dysfunctional blood cells, according to new research. Such a practice coul

      3 min read

    • Article

      How Sugar Causes Cancer

      Jul 18, 2024

      How Sugar Causes Cancer
      4 min read

    • Article

      Don’t Put All Your Eggs In One Basket

      May 23, 2021

      It baffles me how myopic we humans can be when trying to find solutions to some of our biggest challenges. Many thought nuclear power could be a one-stop replacement for fossil fuel, but it turned out to come with numerous problems, especially the ri

      3 min read

    • Article

      Beating Cancer

      Feb 1, 2019

      Is cancer still a death sentence? No. Most cancers are preventable and also treatable. Cancer diagnosis and treatment have grown by leaps and bounds. We know the cause of at least 70 per cent of cancers now, around 60 per cent of cancers are now prev

      4 min read

    • Article

      Doctor Gill

      Jun 26, 2024

      This is a clinical sign of yellow pigmentation of skin, eyes and mucous membranes Jaundice results from raised blood and tissue levels of bilirubin, a by-product of broken-down red blood cells, usually managed by the liver and passed out in bile. It

      3 min read

    • Article

      The Best Integrative Cancer Specialists

      Nov 21, 2021

      The Best Integrative Cancer Specialists
      5 min read

    • Article

      After Big Gains, Cystic Fibrosis Foundation Bankrolls Research Toward Cures — And Drugs For Those Left Out

      Oct 30, 2019

      Last week, the cystic fibrosis community celebrated the approval of another new drug for patients. But, advocates say, much work remains to be done.

      3 min read

    • Article

      Treating The Untreatable Cancers

      Jul 26, 2020

      Treating The Untreatable Cancers
      4 min read

    Related categories

    Reviews for Fast Facts

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words

      Book preview

      Fast Facts - Donal McLornan

      Introduction

      Myelofibrosis (MF) is a ‘Philadelphia chromosome-negative’ myeloproliferative neoplasm that has markedly heterogeneous features. The clinical phenotype can range from initial indolent presentation, which may be stable for many years, through to marked cytopenias, debilitating constitutional symptoms, massive splenomegaly and an inherent risk of leukemic transformation. Many advances focused on MF regarding molecular classification, enhanced prognostication models and available therapeutic options have been made over the last few decades. Suggested management algorithms have become more complex and there are numerous novel agents in advanced clinical trials, hence updated knowledge of these therapeutics is required. Despite these advances, allogeneic stem cell transplantation (allo-SCT) remains the only curative option, yet is suitable only for a minority of patients.

      Within this book we cover key points on epidemiology and clinical presentation, summarize advances in molecular characterization and prognostication, and highlight key advances within the MF therapeutic arena. We also summarize state-of-the-art knowledge on the role of allo-SCT and discuss the most promising agents in clinical trials. The target audience is wide and includes hematologists, oncologists, primary care providers and trainees, as well as pharmacists and specialist nurses in these fields.

      After reading Fast Facts: Myelofibrosis you will:

      •understand how MF presents and progresses, and how to use various risk stratification systems to guide the approach to treatment and assessment of prognosis

      •appreciate the molecular biology underpinning the disease

      •appreciate how to comprehensively assess the impact of overall disease burden, including cytopenia, splenomegaly and other symptoms

      •understand current treatment approaches and the rationales behind them

      •understand the role of allo-SCT

      •understand how blast-phase MF is managed

      •be aware of ongoing clinical trials to assess novel therapeutics for the treatment of MF.

      1Presentation, classification and epidemiology

      Presentation

      Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm (MPN) characterized by a proliferation of abnormal megakaryocytes and granulocytes in the bone marrow, which in overt/fibrotic stages is associated with a polyclonal increase in fibroblasts that drives a secondary marrow fibrosis (reticulin-staining fibrosis ± collagen fibrosis), occasional osteosclerosis and extramedullary hematopoiesis (EMH). On occasion, PMF may present in an earlier prefibrotic state, which is characterized by a hypercellular bone marrow and minimal or absent reticulin fibrosis; many, but not all, of these patients progress to overt PMF. Around 50% of patients managed in clinics with myelofibrosis (MF) will have had antecedent essential thrombocythemia (ET) or polycythemia vera (PV), thus their disease is termed post ET MF (PET-MF) or post PV MF (PPV-MF), respectively. As a collective whole, we refer to the entire population of patients in these categories as having MF.

      MF is a more aggressive condition than ET, PV or indeed prefibrotic/early MF. It is progressive and frequently has profound effects on the quality of life of affected patients. Analogous to the concept of chronic and accelerated phases in chronic myeloid leukemia (CML), it seems likely that PMF represents presentation in an accelerated phase of a previously undiagnosed MPN. Consistent with this concept, patients with PMF harbor more mutations, have more cytogenetic abnormalities and have increased risk of leukemic transformation. Up to one-third of patients are asymptomatic at diagnosis, and many cases are discovered after unrelated blood tests showing modest abnormalities, such as anemia and thrombocytopenia.

      Using globally accepted transformation criteria, rates of myelofibrotic evolution from PV are estimated at 5–14% and cumulative risks of PET-MF are estimated at 9.3% at 15 years.¹ For ET, transformation rates are lower than for PV, with PET-MF frequently occurring later in the disease course. Historically, risk factors for transformation have been based loosely on age, disease duration, use of sequential DNA-damaging agents, cytogenetic anomalies, advancing disease burden and limited genomic profiling, which frequently reveals disparate signatures.²,³

      Splenomegaly is common, progressive and often massive, with the spleen being the commonest site of EMH in PMF. The liver is also usually involved and this can lead to significant hepatomegaly. Other, more unusual sites can sometimes be affected, leading to hematopoietic tumors surrounded by a capsule of connective tissue. Such sites include the lymph nodes, central nervous system, skin, pericardium, peritoneum, pleura, ovaries, kidneys, adrenal glands, gastrointestinal tract and lungs.

      A hypermetabolic state presenting with fevers, anorexia, weight loss and night sweats can develop in many cases of MF, sometimes early on in the disease. Other symptoms are often present, particularly fatigue, bone pain and spleen-related symptoms such as pain and early satiety. The presence of specific symptoms – weight loss, night sweats and fever – is prognostically significant. It is generally recommended that symptoms should be assessed using a specific score such as the MPN-symptom assessment form (MPN-SAF) or MPN10 (see Chapter 5).

      Thrombosis and hemorrhage are also prevalent in patients with PMF and prefibrotic/early MF, in common with MPNs in general. Approximately one-third of patients present with anemia and most will develop it over the course of their disease. It most commonly develops at advanced stages and often coincides with thrombocytopenia. Leukemic transformation occurs in 10–20% of patients and is characterized by the persistent presence of at least 20% blasts in the blood or bone marrow.

      Classification

      The WHO classification system defines major and minor criteria to aid accurate diagnosis (see Table 3.1).⁴ MF is characterized by variable degrees of bone marrow fibrosis accompanied by megakaryocytic atypia and hyperplasia. In the early stages of MF, there is often increased

      Enjoying the preview?
      Page 1 of 1